These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 7203727)

  • 1. Disposition of cefoxitin in the elderly.
    Garcia MJ; Garcia A; Nieto MJ; Dominguez-Gil A; Alonso G; Mellado L
    Int J Clin Pharmacol Ther Toxicol; 1980 Nov; 18(11):503-9. PubMed ID: 7203727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cefoxitin in patients undergoing hemodialysis.
    Garcia MJ; Dominguez-Gil A; Tabernero JM; Bondia Román A
    Int J Clin Pharmacol Biopharm; 1979 Aug; 17(8):366-70. PubMed ID: 489205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefoxitin in patients with normal or impaired renal function.
    Garcia MJ; Dominguez-Gil A; Tabernero JM; Sanchez Tomero JA
    Eur J Clin Pharmacol; 1979 Sep; 16(2):119-24. PubMed ID: 499308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Amikacin (BB-K8) in patients with normal or impaired renal function.
    Lanao JM; Domínguez-Gil A; Tabernero JM; De Castro S
    Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):171-5. PubMed ID: 447438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of cefoxitin in patients with pleural effusion.
    Barrueco M; Garcia MJ; Otero MJ; Dominguez-Gil A; de Letona JM
    Clin Ther; 1981; 3(6):425-35. PubMed ID: 7260988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cefamandole in patients undergoing hemodialysis.
    Campillo JA; Lanao JM; Dominguez-Gil A; Tabernero JM; Rubio F
    Int J Clin Pharmacol Biopharm; 1979 Sep; 17(9):416-20. PubMed ID: 500264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of amikacin (BB-K8) in patients undergoing hemodialysis.
    Lanao JM; Dominguez-Gil A; Tabernero JM; Sanchez Tomero JA
    Int J Clin Pharmacol Biopharm; 1979 Aug; 17(8):357-60. PubMed ID: 489203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefoxitin in patients with pleural effusion on a multiple dosage regimen.
    Garcia MJ; Otero MJ; Barrueco M; Dominguez-Gil A
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):300-3. PubMed ID: 6746153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of cefoxitin administered intramuscularly to rabbits with experimentally-induced renal impairment.
    Garcia MJ; Dominguez-Gil AA; Cepeda M; Dominguez-Gil A
    Biopharm Drug Dispos; 1981; 2(3):205-13. PubMed ID: 7295878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of acute renal impairment in the penetration of cefoxitin into interstitial tissue fluid in rabbits.
    Dominguez-Gil AA; Garcia MJ; Cepeda M; Lanao JM; Dominguez-Gil A
    Clin Ther; 1981; 3(6):413-24. PubMed ID: 7260987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition kinetics of amikacin in patients with renal impairment after intramuscular administration.
    Lanao JM; Dominguez-Gil A; Tabernero JM; Molina HD
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):271-5. PubMed ID: 7107075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of experimentally induced renal impairment on the pharmacokinetics of cefadroxil in rabbits.
    Mariño EL; Dominguez-Gil AA; Cepeda M; Otero MJ; Dominguez-Gil A
    Arzneimittelforschung; 1981; 31(3):478-81. PubMed ID: 7194673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of age on the early disposition of doxorubicin.
    Li J; Gwilt PR
    Cancer Chemother Pharmacol; 2003 May; 51(5):395-402. PubMed ID: 12679882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of cefoxitin in patients with ascites.
    Garcia MJ; Dominguez-Gil A; Perez FD; Rodriguez FP; Moronta FD
    Eur J Clin Pharmacol; 1981; 20(5):371-4. PubMed ID: 7286047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cefoxitin administered by i.v. infusion to patients with a pleural effusion.
    Otero MJ; Garcia MJ; Barrueco M; Dominguez-Gil A; Gomez F; Portugal Alvarez J
    Eur J Clin Pharmacol; 1984; 26(3):389-92. PubMed ID: 6734700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of single-dose cefotetan and multidose cefoxitin as intravenous prophylaxis in elective, open biliary tract surgery: a multicentre, double-blind, randomized study.
    Lapointe RW; Roy AF; Turgeon PL; Lewis RT; Dagenais MH; Joly JR; Scudamore CH; Roy PD; Conly JM; Syrotuik J
    Can J Surg; 1994 Aug; 37(4):313-8. PubMed ID: 8055389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of single doses of cefoxitin given by the intravenous and intramuscular routes to unweaned calves.
    Soback S
    J Vet Pharmacol Ther; 1988 Jun; 11(2):155-62. PubMed ID: 3054149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a double-blind, placebo-controlled clinical trial program of single-dose ceftizoxime versus multiple-dose cefoxitin as prophylaxis for patients undergoing vaginal and abdominal hysterectomy.
    McGregor JA; Phillips LE; Roy S; Dunne JT; Warwaruk AS; Johnston DW; Yuzpe AA; Hemsell DL
    J Am Coll Surg; 1994 Feb; 178(2):123-31. PubMed ID: 8173721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of ascites on the pharmacokinetics of amikacin.
    Lanao JM; Dominguez-Gil A; Macias JG; Diez JL; Nieto MJ
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(2):57-61. PubMed ID: 7372376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.